Neuromyelitis Optica Market

Market Overview:

The 7 major neuromyelitis optica markets reached a value of US$ 299.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 469.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.17% during 2024-2034.

The neuromyelitis optica market has been comprehensively analyzed in IMARC's new report titled "Neuromyelitis Optica Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neuromyelitis optica refers to a rare autoimmune disease affecting the central nervous system, specifically the optic nerves and spinal cord. In this case, the immune system attacks the myelin sheath that protects the nerve fibers, leading to inflammation, demyelination, and nerve damage. The common indications of the ailment include weakness or numbness in the arms and legs, pain in the eyes, loss of vision, paralysis of the legs and arms, difficulty controlling the bladder or bowels, etc. Individuals suffering from neuromyelitis optica may also experience confusion, spasticity, sexual dysfunction, hearing loss, uncontrollable hiccups or itching, vertigo, etc. The diagnosis of this condition is based on a review of the patient's symptoms, along with a neurological and physical exam. Several diagnostic imaging studies are utilized to identify lesions in the spinal cord and optic nerves that are characteristic of the ailment. Additionally, various laboratory tests are performed to detect the presence of antibodies that target a protein called aquaporin-4 (AQP4), which are present in most patients. In some cases, a spinal tap (lumbar puncture) is also done to analyze the cerebrospinal fluid for signs of inflammation.

The rising cases of autoimmune disorders, which cause the body's defense system to attack healthy cells by defect, are primarily driving the neuromyelitis optica market. In addition to this, the escalating prevalence of various risk factors, such as vitamin D deficiency, chain smoking, gastrointestinal infections, etc., is also bolstering the market growth. Furthermore, the widespread adoption of immunosuppressive drugs, including mycophenolate mofetil and rituximab, for treating the disease is acting as another significant growth-inducing factor. These agents mainly target T and B cell functions to eliminate proinflammatory molecules from the peripheral bloodstream and prevent attacks. Additionally, several key players are making extensive investments in R&D activities to launch novel technologies that facilitate an improved understanding of the immunopathological mechanisms underlying the illness. This, in turn, is creating a positive outlook for the market. Moreover, the emerging popularity of monoclonal antibodies, such as anti-CD19 and anti-interleukin-6, owing to their numerous advantages, including enhanced safety, lower toxicity, and improved patient outcomes, is further expected to drive the neuromyelitis optica market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the neuromyelitis optica market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for neuromyelitis optica and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuromyelitis optica market in any manner.

Recent Developments:

• In March 2024, Alexion, AstraZeneca Rare Disease announced that its ULTOMIRIS (ravulizumab-cwvz) was licensed in the United States as the first and only long-acting C5 complement inhibitor for the management of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum illness.
• In January 2024, Horizon Therapeutics plc stated that on December 15, 2023, Health Canada approved UPLIZNA (inebilizumab for injectable) as a monotherapy for adult individuals with neuromyelitis optica spectrum disorders who are AQP4-IgG+.

Key Highlights:

• Neuromyelitis optica spectrum disorder has a global distribution with an estimated prevalence of 1-5/100,000.
• The average annual incidence worldwide is 1/770,000.
• Approximately 90% of those affected with neuromyelitis optica are female.
• East Asians tend to have a higher prevalence of neuromyelitis optica (approximately 3.5/100,000) than Whites and other Asian racial groups.
• The average age at onset of neuromyelitis optica was noted to be 41.1 years

Drugs:

Soliris (eculizumab) refers to a first-in-class C5 complement inhibitor used to treat neuromyelitis optica. The medicine inhibits the C5 protein in the terminal complement cascade, which is a part of the body's immune system. When stimulated in an uncontrolled manner, the terminal complement cascade overreacts, leading the body to attack its healthy cells. Soliris is given intravenously every two weeks after an introductory dosage period.

Telitacicept is RemeGen's proprietary new fusion protein used to treat autoimmune disorders. It is made up of the extracellular domain of the human transmembrane activator, calcium modulator, and cyclophilin ligand interactor (TACI) receptor and the Fc domain of human immunoglobulin G (IgG).

HBM9161 is an antibody that targets the neonatal Fc receptor (FcRn). FcRn expression prolongs the half-life of IgGs and serum albumin by inhibiting lysosomal degradation in endothelial and bone marrow-derived cells. Blocking the FcRn-IgG connection accelerates autoantibody degradation and alleviates flare-ups in preclinical models of a wide range of pathogenic IgG-mediated autoimmune disorders, including neuromyelitis optica spectrum disorder.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the neuromyelitis optica market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the neuromyelitis optica market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current neuromyelitis optica marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the neuromyelitis optica market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the neuromyelitis optica market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the neuromyelitis optica market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of neuromyelitis optica across the seven major markets?
• What is the number of prevalent cases (2018-2034) of neuromyelitis optica by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of neuromyelitis optica by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with neuromyelitis optica across the seven major markets?
• What is the size of the neuromyelitis optica patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of neuromyelitis optica?
• What will be the growth rate of patients across the seven major markets?
   

Neuromyelitis Optica: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for neuromyelitis optica drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuromyelitis optica market?
• What are the key regulatory events related to the neuromyelitis optica market?
• What is the structure of clinical trial landscape by status related to the neuromyelitis optica market?
• What is the structure of clinical trial landscape by phase related to the neuromyelitis optica market?
• What is the structure of clinical trial landscape by route of administration related to the neuromyelitis optica market?